Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
about
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's diseaseCerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseValue of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosisAn update on the diagnosis and treatment of Parkinson diseaseDiagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's DiseaseMonitoring of 30 marker candidates in early Parkinson disease as progression markers.The role of biomarkers and imaging in Parkinson's disease.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severityLewy body dementias.CSF biomarkers and clinical progression of Parkinson disease.Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's diseaseAbnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Onset of Mild Cognitive Impairment in Parkinson Disease.Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease.COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progAssociations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Review: Parkinson's disease: from synaptic loss to connectome dysfunction.Cognitive decline in Parkinson disease.Plasma α-synuclein predicts cognitive decline in Parkinson's disease.Parkinson disease and cognitive impairment: Five new things.Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.Mild cognitive impairment in Parkinson's disease: a distinct clinical entity?Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism.Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias.An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.
P2860
Q21131066-EC0FF9CA-90BB-4683-A950-0A8B532F60F2Q26744782-919C6E27-D586-435B-BDC6-3C1F46F30545Q28082380-6B60C061-DF28-46B1-9C10-8839EB486755Q30243899-70C43127-C8C9-4D66-AB21-A5B8E234902EQ30659251-ADF74EDD-87FF-4148-8D1F-04A6B1A4F636Q30783504-9E206640-ECC0-4BFF-BE2F-5528B37D8012Q31041660-573D41AA-EE6E-40CA-AF87-112979A11D7CQ31097119-8CAF8D3A-FC13-4F3A-A1A6-37B00941225EQ33917300-4582C46B-2FF1-428D-AE19-370623AF77CFQ34460662-C8BB5ECB-3DED-4AC9-BA57-CB603823B2E4Q34502646-D71290C1-DA7A-471B-96F9-953ED2961A4CQ35106542-5B90D5C4-497E-4B76-AF0E-5E72192EBCF0Q35597118-DF4AC6E6-BB2D-422B-8020-A267EA4DC91AQ35897340-0495CCA7-5C01-43E9-8F9D-BAA7B0A9CC1CQ35969183-FB1A6A58-1212-49FA-A936-A16FDB342272Q36118812-92E13A55-400D-4124-8B3E-68C1885C8751Q36276502-2EF1C967-205D-4F27-A7BD-AF9EFD585272Q36616565-821D9DAA-C01A-404A-A861-409A5D583979Q37273088-D87821CD-3F93-4DF1-8D12-7D0D7940196CQ37345484-2278B5D6-988E-48BA-8D6C-09F5B473640DQ37494873-9E8758C2-A6B6-4F6F-BFCD-6870DD1DD536Q38271572-1345EA2B-31CB-40CE-9777-EBD9EB14DB5AQ38421118-B51CB1FD-7726-477A-AEE2-463116005FD7Q38603309-B8F86DC4-A41C-4D1E-BFD7-F99A6E15B93FQ38650395-5ADACD5E-6D71-409C-AF9E-EB06C7301F31Q38751099-FCA0C484-78BD-4E50-931A-0370DE2423C4Q38760749-84D4DE37-CE8E-4098-8F1D-030CF4F7234FQ39009679-7C4F8F92-AF0E-42DA-ADA1-3EC4C343C273Q39170813-5E774FB7-D4F4-4B69-8853-4E8AEEEF862EQ39366291-E30F59DE-EAC1-4FE3-AA89-E9C63D9C8DBEQ39466212-8627F2C7-74E9-4F42-8700-D474550E93EBQ40750313-1F55F152-2B9D-4844-91D7-3D8B8180A3B9Q41152157-436CB074-642D-454E-A5CE-56C076E40E61Q42181834-3382175B-C91D-4036-83CA-7E9FB2261FC5Q46012657-E75D1685-28DB-4F34-88E6-DB557F77773EQ47338262-2854284E-3D41-4FBB-A246-847C12935DB7Q47619917-8751B3F9-2CD0-4424-BBFC-954BB75BDA4CQ47923287-5B2BBCDD-2A30-4046-9F87-917F0F8D8A65Q47941297-394CF8A1-2BE1-4354-B4A5-D28D3FEE13ADQ48238518-B8DB72A7-BF14-4C55-BDE6-59E1258B305E
P2860
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@ast
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@en
type
label
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@ast
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@en
prefLabel
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@ast
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@en
P2093
P2860
P921
P1476
Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.
@en
P2093
Brenna Cholerton
Carmen Ginghina
Kevin C Cain
Parkinson Study Group DATATOP Investigators
Peggy Auinger
Tessandra Stewart
P2860
P304
P356
10.1016/J.AJPATH.2013.12.007
P407
P577
2014-03-11T00:00:00Z